CVS Health (CVS) is positioning itself as a compelling value stock, despite its shares lagging behind the S&P 500 this year. While the market has focused on its low-margin pharmacy business, CVS is evolving into a diversified healthcare powerhouse, leveraging its pharmacy benefits management through CVS Caremark and health insurance via Aetna. With a forward P/E ratio of under 11, the stock appears undervalued, especially as it reported record sales of $402.1 billion in 2025 and anticipates adjusted EPS growth to $7.00-$7.20 in 2026.
The company’s robust cash flow supports its 3.46% dividend yield, which has increased by 33% since 2022. Additionally, a higher-than-expected Medicare payment rate increase could enhance margins for Aetna, further solidifying CVS’s financial outlook. As CVS prepares for its first-quarter earnings report on May 6, it could potentially announce a dividend increase or stock buyback, making it an attractive option for value and income-focused investors.
Source: fool.com